Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3YG5P)

Drug Name
GYKI-52466 Drug Info
Synonyms
Gyki-52466; 102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2
Cross-matching ID
PubChem CID
3538
ChEBI ID
CHEMBL79560
CAS Number
CAS 102771-26-6
TTD Drug ID
D0A9VO

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.14 0.00e+0 93/133 (69.92%) ATP6V1G1;ATP5PD;NDUFB5;...
Fanconi anemia pathway 2.01 7.16e-3 36/54 (66.67%) RPA3;USP1;BLM;...
Base excision repair 1.87 3.10e-2 29/33 (87.88%) PCNA;POLE3;MPG;...
DNA replication 1.86 2.86e-2 34/36 (94.44%) RPA3;PCNA;POLE3;...
Citrate cycle (TCA cycle) 1.82 2.58e-2 30/30 (100%) DLD;IDH2;SUCLA2;...
Parkinson disease 1.80 2.50e-2 176/249 (70.68%) PPIF;VDAC1;ATP5PD;...
Nucleotide excision repair 1.78 2.45e-2 40/47 (85.11%) RPA3;PCNA;POLE3;...
Pyrimidine metabolism 1.75 2.59e-2 40/56 (71.43%) RRM2;RRM1;ENPP1;...
Prion disease 1.73 2.62e-2 209/273 (76.56%) C1QA;PPIF;C1QB;...
Purine metabolism 1.66 4.22e-2 102/129 (79.07%) AK4;PDE10A;GUCY1A1;...
Ras signaling pathway -1.77 4.17e-2 201/232 (86.64%) MET;GNB3;PIK3CA;...
Focal adhesion -1.79 3.51e-2 180/201 (89.55%) COL4A4;ITGB1;LAMC1;...
Hematopoietic cell lineage -1.85 2.19e-2 90/99 (90.91%) IL7;CD7;CSF1;...
Adherens junction -1.88 2.09e-2 63/71 (88.73%) LEF1;SNAI1;SMAD3;...
MAPK signaling pathway -1.93 1.25e-2 272/294 (92.52%) CSF1;MAP4K4;TP53;...
Cell adhesion molecules -1.97 1.25e-2 118/148 (79.73%) PTPRC;SELE;HLA-F;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H